GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump
08/12/2022 | 04:24am EDT
LONDON (Reuters) - Shares in GSK, Sanofi <SASY.PA and Haleon began to stabilise on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.
The companies' share prices had fallen sharply this week on investor concern about the litigation over potential cancer-causing impurities that prompted the drug's withdrawal from markets in 2019 and 2020. The first U.S. trial is expected to start this month.
(Reporting by Natalie Grover in London; Editing by David Goodman)